|
When ultrasonic technology was first introduced in lipoplasty, there was excitement about its potential to transform a procedure that relied on mechanical avulsion and suction to one with more finesse. Unfortunately, like many new technologies, earlier generation products had limitations. Fragmentation of fat with smooth solid probes followed by suction generally lacked efficiency (click here to learn more about the VASER System's proprietary grooved probes). Later, larger hollow probes performing simultaneous emulsification and suction resulted in complications such as tissue burns and seromas, which created concerns within the medical community regarding the safety of ultrasonic technology for fat removal. Now, after years of research and development, and thousands of patients, there is finally an ultrasonic body shaping technology and surgical technique designed to provide precise and efficient sculpting: VASER LipoSelection®.
 |
| Graphic interpretation of intact connective tissue following VASER LipoSelection® treatment. |
Tissue selectivity is the key. The VASER System's advanced ultrasound technology creates an efficient way of breaking down fatty tissue before it is removed. A patented grooved probe transmits ultrasound energy around the entire grooved tip - not just from the end - for greater emulsification with diminished risk of excess tissue trauma. The wetting solution infused prior to the procedure provides thermal protection and aids in the formation of the emulsion. Using the VASER Pulse mode, the amount of energy delivered to tissues is lower - without sacrificing efficiency. And, because ultrasound technology is tissue selective, important tissues are left relatively intact.
Because blood vessels and nerves are minimally disrupted, patients report little bruising and low to minimal pain. VASER Technology is efficient on different types of fatty tissue, from the most fibrous areas of the back and chest to delicate areas like the arms, inner thighs, chin, and neck. An independent peer-reviewed study reported a low incidence of re-treatment rates. |
